拉米夫定治疗失败的乙型肝炎合并感染HIV的青少年对替诺福韦的反应
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
作者信息
Aurpibul Linda, Lumbiganon Pagakrong, Hansudewechakul Rawiwan, Kanjanavanit Suparat, Bunupuradah Torsak, Kosalaraksa Pope, Taeprasert Pawinee, Puthanakit Thanyawee
机构信息
From the *Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; †Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; ‡Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand: §Nakornping Hospital, Chiang Mai, Thailand; ¶The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), the Thai Red Cross AIDS Research, Bangkok, Thailand; and ‖Department of Pediatrics, Faculty of Medicine, and Research Unit in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand.
出版信息
Pediatr Infect Dis J. 2017 Apr;36(4):401-404. doi: 10.1097/INF.0000000000001491.
We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
我们测定了18例曾使用拉米夫定（3TC）的乙型肝炎病毒（HBV）与人类免疫缺陷病毒合并感染的青少年在接受富马酸替诺福韦二吡呋酯（TDF）治疗后的HBV抑制率。开始使用TDF时，他们的中位年龄为17.6岁，3TC暴露时间为7.3年。11例患者（61%）在接受TDF和3TC联合治疗48周后实现了HBV DNA<60 IU/mL，这与成人研究结果相似，不过未出现乙肝表面抗原消失或乙肝e抗原血清学转换。
Zotero 插件